Aldeyra Therapeutics, Inc. announced positive top-line results from the Phase 3 INVIGORATE-2 Clinical Trial of 0.25% reproxalap ophthalmic solution (reproxalap), an investigational new drug, in patients with allergic conjunctivitis. The clinical trial successfully achieved statistical significance for the primary endpoint and all secondary endpoints. The randomized, double-masked, vehicle-controlled, two-way crossover design allergen chamber Phase 3 INVIGORATE--2 Trial enrolled 131 allergic conjunctivitis patients.

The primary efficacy endpoint was change from baseline in patient-reported ocular itching score on a 0--4 point scale over a majority of 11 timepoints from 110 to 210 minutes after allergen chamber entry. The key secondary endpoint was change from baseline in ocular redness on a 0--4 point scale over the duration of the allergen chamber (approximately 3.5 hours). Relative to patients treated with vehicle, patients treated with reproxalap reported statistically significant ocular itching score reduction across all 11 prespecified primary endpoint comparisons (P<0.0001 for each comparison) from 110 to 210 minutes in the allergen chamber.

The reproxalap-treated patients demonstrated statistically significant reduction from baseline compared to vehicle (P=0.004) for the key secondary endpoint of investigator-assessed ocular redness over the duration of the allergen chamber. Statistical significance was also achieved for the two secondary endpoints of change from baseline in patient-reported ocular tearing score on a 0--3 point scale over the duration of the allergen chamber (P<0.0001) and change from baseline in total ocular severity score (11--point composite of the itching, redness, and tearing scores) over the duration of the allergen chamber (P<0.0001). Reproxalap ophthalmic solution has now been administered to more than 2,400 patients across 21 clinical trials.

Consistent with prior clinical experience with reproxalap, there were no observed safety or tolerability concerns in the INVIGORATE-2 Trial; the most common adverse event was mild and transient instillation site irritation. No patients discontinued due to adverse events, and 130 of 131 randomized patients completed the clinical trial. A New Drug Application (NDA) of reproxalap for the treatment of dry eye disease is under review at the U.S. Food and Drug Administration.

The NDA Prescription Drug User Fee Act (PDUFA) date for reproxalap for the treatment of dry eye disease is November 23, 2023.